Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEBiotechnology
-$0.26 today
- Market cap
- $761.36M
- Beta
- 1.60
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.98
Volume 1.11M
Average 1.02M
Returns on capital
Monte Rosa Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-16.6%
avg -6.6%
ROIC
-13.6%
avg -56.9%
ROA
-8.6%
avg -38.1%
Analysis
ROA is currently the strongest return metric at -8.6% versus its period average of -38.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Markus Warmuth | President, Chief Executive Officer & Director | USD 1.08M | 55 | 585.04K | 0.90% |
Filip Janku | Chief Medical Officer | USD 833.6K | 52 | 60.61K | 0.09% |
Phil Nickson | Chief Business & Legal Officer | USD 833.6K | 47 | — | — |
Sharon Townson | Chief Scientific Officer | USD 644.6K | 51 | 67.84K | 0.10% |
John C. Castle | Chief Data & Information Officer | — | 55 | 78.50K | 0.12% |
Andrew Funderburk | Chief Investor Relations and Strategy Officer | — | — | — | — |
Magnus Walter DPHIL | Chief Technology Officer | — | — | — | — |
Matthew Bowen | Corporate Controller & Principal Accounting Officer | — | 37 | 25.89K | 0.04% |
Jennifer Champoux | Chief Operating Officer | — | 54 | 26.95K | 0.04% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
37
$4.11M
Net Transaction Value
−$4.11M
Net selling
Most Active
Warmuth Markus
10 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 5, 26Oct 5, 2026 | Bowen Matthew Direct | Sell | $137.3$137.28 |
| Jul 16, 26Jul 16, 2026 | Warmuth Markus Direct | Sell | $220.2K$220,218.55 |
| Jul 15, 26Jul 15, 2026 | Champoux Jennifer Direct | Sell | $101.7K$101,729.86 |
| Jul 6, 26Jul 6, 2026 | Townson Sharon Direct | Sell | $130.2K$130,197.20 |
| Jul 6, 26Jul 6, 2026 | Townson Sharon Direct | Sell | $9.7K$9,652.00 |
| Jun 30, 26Jun 30, 2026 | Janku Filip Direct | Sell | $132.5K$132,471.50 |
| Jun 29, 26Jun 29, 2026 | Janku Filip Direct | Sell | $137.7K$137,700.00 |
| Jun 29, 26Jun 29, 2026 | Manning Anthony M. Direct | Sell | $231.1K$231,100.00 |
| Jun 24, 26Jun 24, 2026 | Janku Filip Direct | Sell | $642.7K$642,681.00 |
| Jun 23, 26Jun 23, 2026 | Janku Filip Direct | Sell | $239.5K$239,522.48 |
1–10 of 37
Summary
Insiders reported 0 buys worth $0.00 and 37 sells worth $4.11M over the last 12 months. That adds up to net selling of $4.11M. Warmuth Markus was the most active insider with 10 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +2.3% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +2.3% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Monte Rosa Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about GLUE's management, answered from reported figures.
Who manages GLUE?
Monte Rosa Therapeutics, Inc. (GLUE) lists 9 active executives. The top listed executive is Sharon Townson, Chief Scientific Officer.
Are GLUE insiders buying or selling?
Recent insider activity shows net buying of $20.21M.
Continue the stock analysis
Jump to another research area for this company.